19036
document
Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer . UNLABELLED Today , androgen deprivation therapy is a cornerstone of treatment for advanced prostate cancer , although it presents important complications such as osteoporosis . Neridronate , a relatively new bisphosphonate , is able to prevent bone loss in patients with prostate cancer during androgen ablation . INTRODUCTION Androgen-deprivation therapy ( ADT ) is a cornerstone of treatment for advanced prostate cancer . This therapy has iatrogenic complications , such as osteoporosis . The aim of our study was to evaluate the efficacy of neridronate , a relatively new bisphosphonate , to prevent bone loss during androgen ablation . MATERIALS AND METHODS Forty-eight osteoporotic patients with prostate cancer , treated with 3-month depot triptorelina , were enrolled and randomly assigned to two different treatment groups : group A ( n = 24 ) was treated with a daily calcium and cholecalciferol supplement ( 500 mg of elemental calcium and 400 IU cholecalciferol ) , and group B ( n = 24 ) received in addition to the same daily calcium and cholecalciferol supplement , 25 mg of neridronate given intramuscularly every month . All patients also received bicalutamide for 4 weeks . Lumbar and femoral BMD was evaluated by DXA at baseline and after 1 year of therapy ; moreover , deoxypyridinoline ( DPD ) and bone alkaline phosphatase ( BALP ) were determined at the beginning , midway through , and at the end of the study . RESULTS After 6 and 12 months , whereas patients treated only with calcium and cholecalciferol ( group A ) showed a marked bone loss , with increased levels of DPD and BALP compared with baseline values , patients treated also with neridronate ( group B ) had substantially unchanged levels of these markers . After 1 year of treatment , lumbar and total hip BMD decreased significantly in patients treated only with calcium and cholecalciferol ( group A ) , whereas it did not change significantly at any skeletal site in patients treated also with neridronate ( group B ) . No relevant side effects were recorded during our study . CONCLUSIONS Neridronate is an effective treatment in preventing bone loss in the hip and lumbar spine in men receiving ADT for prostate cancer .
19037
Intervention_Pharmacological
Neridronate
19038
Intervention_Pharmacological
androgen deprivation therapy
19039
Intervention_Pharmacological
Neridronate
19040
Intervention_Pharmacological
bisphosphonate
19041
Intervention_Pharmacological
triptorelina
19042
Intervention_Pharmacological
daily calcium and cholecalciferol supplement
19043
Intervention_Pharmacological
daily calcium and cholecalciferol supplement
19044
Intervention_Pharmacological
bicalutamide
19045
Intervention_Pharmacological
Neridronate
19046
Outcome_Physical
bone loss
19047
Outcome_Physical
osteoporosis
19048
Outcome_Physical
bone loss
19049
Outcome_Other
efficacy
19050
Outcome_Physical
Lumbar and femoral BMD
19051
Outcome_Physical
deoxypyridinoline ( DPD ) and bone alkaline phosphatase ( BALP )
19052
Outcome_Physical
marked bone loss
19053
Outcome_Physical
increased levels of DPD and BALP
19054
Outcome_Physical
lumbar and total hip BMD decreased significantly
19055
Outcome_Other
change significantly
19056
Outcome_Adverse-effects
relevant side effects
19057
Outcome_Physical
bone loss
19058
Participant_Condition
prostate cancer
19059
Participant_Condition
advanced prostate cancer
19060
Participant_Condition
prostate cancer
19061
Participant_Condition
advanced prostate cancer
19062
Participant_Sample-size
Forty-eight
19063
Participant_Condition
prostate cancer
19064
Participant_Sample-size
24
19065
Participant_Sample-size
24
19066
Participant_Condition
prostate cancer .